Pasteur Institute Competitors

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to complianceofficer@drreddys.com or chiefombudsperson@drreddys.com. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

The Indian Institute of Science (IISc) was founded in 1909 as a result of the joint efforts of Jamsetji Nusserwanji Tata, the Government of India, and the Maharaja of Mysore. In 1886, Jamsetji Tata conceived of a university of science that would work for the benefit of India, and in 1898 created an endowment for establishing such an institution. The Government of India then took up the effort, and, in consultation with scientists in England and in India, decided to locate the Institute in Bengaluru, where the Maharaja of Mysore, Shri Krishnaraja Wodeyar IV, donated 372 acres of land. The Institute was formally vested in 1909, the foundation stone was laid in 1911, and the first batch of students started their studies in the same year. Over the last century, IISc has become the premier institute for advanced scientific and technological research and education in India. Beginning with 2 departments and 21 students in 1911, today IISc has 39 departments, units, or centres, 3500 students, and about 500 academic and scientific staff, supported by 600 administrative personnel. About 2200 students are in various PhD programs, almost 900 are enrolled for various Masters degrees, whereas about 400 are registered in the newly established, research oriented, four-year Bachelor of Science (Research) programme. In recent years, the Institute has vigorously promoted interdisciplinary research. New centres such as the CiSTUP, the Robert Bosch Centre for Cyber Physical Systems and a new Centre for Brain Research (funded by a large private endowment) are expected to conduct translational research in their respective areas, in order to better connect with industry and society. With the recent construction of modern buildings, acquisition of new research facilities, and induction of a large number of new faculty members, the Institute can look forward to an era of high productivity, increasing impact, and rising prominence in the world.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last seven decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia. For more information visit: https://www.cadilapharma.com/